Advertisement

Journal of Gastrointestinal Cancer

, Volume 50, Issue 4, pp 860–866 | Cite as

Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?

  • Daniel M. GirardiEmail author
  • Luiza Dib B. B. Faria
  • Marcela C. Teixeira
  • Frederico P. Costa
  • Paulo Marcelo G. Hoff
  • Gustavo S. Fernandes
Original Research

Abstract

Purpose

Advanced pancreatic adenocarcinoma (PA) is an aggressive disease that has poor prognosis and frequently interferes with patient’s quality of life. There has been progress in first-line regimens; however, there is no standard second-line regimen. The aim of this study is to analyze second-line gemcitabine after first-line fluorouracil (FU) + leucovorin (LV) + irinotecan + oxaliplatin (FOLFIRINOX) regimen.

Methods

This study included consecutive patients with advanced PA treated at Hospital Sirio-Libanês from 2011 to 2016. The patients received FOLFIRINOX as first-line treatment and upon progression, received gemcitabine alone. Survival analysis was performed using the Kaplan-Meier method.

Results

A total of 54 patients were evaluated. Most patients were male (61.1%) and most had an ECOG performance status of 0 or 1 prior to the beginning of second-line treatment (66.6%). The mean number of gemcitabine cycles was 3.4. Most patients had disease progression as the best response to treatment (75.9%), 11.1% had stable disease, and 9.3% experienced a partial response. The median progression-free survival was 1.7 months, and the median overall survival was 6.8 months.

Conclusions

Gemcitabine alone did not show meaningful clinical benefit as second-line treatment after FOLFIRINOX.

Keywords

Gemcitabine FOLFIRINOX Second-line treatment Pancreatic 

Notes

Acknowledgements

The Oncology Center of Hospital Sírio-Libanes supported this work.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with Ethical Standards

Conflict of Interest

Gustavo dos Santos Fernandes has received grants for consulting or Advisory Role from Roche, has received a speaker honorarium from Roche, has provided expert testimony for Novartis, and received travel accommodations and expenses from Roche. The rest of the authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

References

  1. 1.
    Popp FC, Popp MC, Zhao Y, Betzler C, Kropf S, Garlipp B, et al. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease. BMC Cancer. 2017;17(1):229.CrossRefGoogle Scholar
  2. 2.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefGoogle Scholar
  3. 3.
    Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. WITHDRAWN: chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2009;07(4):CD002093.Google Scholar
  4. 4.
    Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(6):2403–13.CrossRefGoogle Scholar
  5. 5.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRefGoogle Scholar
  6. 6.
    Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(23):2423–9.CrossRefGoogle Scholar
  7. 7.
    Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of 5-fluorouracil/Leucovorin with or without Oxaliplatin for second-line advanced pancreatic Cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3914–20.CrossRefGoogle Scholar
  8. 8.
    Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase III trial. Lancet. 2016;387:545–57.CrossRefGoogle Scholar
  9. 9.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefGoogle Scholar
  10. 10.
    Viaud J, Brac C, Artru P, Le Pabic E, Leconte B, Bodère A, et al. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: a retrospective study. Dig Liver Dis. 2017;49(6):692–6.  https://doi.org/10.1016/j.dld.2017.02.007.CrossRefPubMedGoogle Scholar
  11. 11.
    Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, et al. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore). 2017;96(16):e6544.  https://doi.org/10.1097/MD.0000000000006544.CrossRefGoogle Scholar
  12. 12.
    Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with FOLFIRINOX for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917–24.  https://doi.org/10.3892/ol.2017.6061.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Da Rocha Lino A, Abrahão CM, Brandão RM, Gomes JR, Ferrian AM, Machado MCC, et al. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. J Gastrointest Oncol. 2015;6(5):511–5.  https://doi.org/10.3978/j.issn.2078-6891.2015.041. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, Fouchardière C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113:989–95.CrossRefGoogle Scholar
  15. 15.
    Zhang Y, Hochster H, Stein S, Lacy J. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol. 2015;4:29.CrossRefGoogle Scholar
  16. 16.
    Bertocchi P, Abeni C, Meriggi F, Rota L, Rizzi A, Di Biasi B, et al. Gemcitabine plus nab-paclitaxel as second-line and beyond treatment for metastatic pancreatic cancer: a single institution retrospective analysis. Rev Recent Clin Trials. 2015;10:142–5.CrossRefGoogle Scholar
  17. 17.
    Nguyen KT, Kalyan A, Beasley HS, Singhi AD, Sun W, Zeh HJ, et al. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer—retrospective analysis of response. J Gastrointest Oncol. 2017;8(3):556–65.  https://doi.org/10.21037/jgo.2017.01.23.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OncologyHospital Sírio-LibanesBrasíliaBrazil
  2. 2.Instituto do Câncer do Estado de São PauloFaculdade de Medicina da Universidade de São PauloSão PauloBrazil

Personalised recommendations